The Patent Finder

Terms ending in 2030

DCB-USA LLC

Every in-force patent on DCB-USA LLC's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,241,608Treating Allergy with Detoxified E. Coli Heat-Labile Enterotoxin
In force
 · High confidence
Development Center for BiotechnologyIn forceHigh confidence
US 8,119,683Aryl Substituted Sulfonamide Compounds and Their Use as Anticancer Agents
In force
 · High confidence
Taipei Medical University, DCB-USA LLC and National Health Research InstitutesIn forceHigh confidence
US 9,315,491Novel Pyrimidine Compounds as Mtor and PI3K Inhibitors
In force
 · High confidence
Development Center for BiotechnologyIn forceHigh confidence
US 9,801,888Novel Pyrimidine Compounds as Mtor and PI3K Inhibitors
In force
 · High confidence
Development Center for BiotechnologyIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by DCB-USA LLC.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited